

WORKSHOP 1 REPORT
Studying Service and
Pharmaceutical Care Delivery

Cecilia BERNSTEN

Suzete COSTA

Rationale

- **Legal framework for pharmacy going through unprecedented changes across Europe**
- **European pharmaceutical market growing at a slower rate**
- **Pressure to change or reduce pharmacy margins**
- **Pharmacists need:**
 - **new strategies in order to be paid for providing certain professional services within the pharmacy setting**
 - **to focus on services that meet the needs of the population and can be fit into their business in a sustainable manner**
 - **to be creative and learn how to use innovations**
- **Research needs to be on top of changes, moving WITH changes, not AFTER changes have occurred...**

Research areas chosen

Innovative services likely to impact Pharmacy Practice in coming years

1. WG 1 - Centrally approved switches to non-prescription products in Europe (First: orlistat)
2. WG 2 - Home medicines delivery and pharmaceutical care provision in this context

GOALS:

1. **To produce a draft protocol, for each WG, for a possible research study involving interested countries.**
2. **If possible, to further develop inter-country collaborative project under the PCNE umbrella.**

Project Plan

- Title
- Background (based on literature search)
- Research question
- Aim(s)
- Objectives 1, 2, 3
- Study design
- Subjects and settings
- Data collection methods 1, 2, 3, 4, 5, 6
- Analysis of findings (statistics, analysis methods..)
- Researcher (s), Collaborators
- Timeframe
- Costs
- Approvals needed (ethical, organizational, authorities, etc, etc)

WG 1 - Centrally approved switches to non-prescription products in Europe (First: orlistat)

- Title: Safety and effectiveness issues of switches to non prescription. The orlistat case.
- Background: First central switch – community pharmacy challenge
- Research question: What are the patient safety and effectiveness issues in the case of switching complex medicines, such as orlistat, to non-prescription status?
- Aim(s): To determine differences in patient safety and effectiveness of treatment with orlistat purchase between pharmacies with standard operating procedure (SOP) vs. pharmacies with no SOP vs. other outlets
- Objectives 1, 2, 3
- Study design: Controlled trial
- Timeframe (if inter-country project): March 2009 – December 2010

WG 2 – Home medicines delivery and pharmaceutical care provision in this context

- Title: Is home delivery service of medicines a blessing?
- Background: Patients with chronic diseases and polimedication are at a high risk of DRPs. Little is known about the need of PC among HDM patients.
- Research question: What is the need of PC in HDM patients?
- Aim (s): To analyse the need of PC in HDM patients
- Objectives 1, 2, 3
- Study design: Intervention study without control group
- Time frame:

Workshop participants (hard workers)

WG 1 - Centrally approved switches to non-prescription products in Europe (First: orlistat):

CALABUIG, Aranzazu Noain (Spain)
CAVACO, Margarida (Portugal)
COSTA, Suzete (Portugal)
DAUKSIENE, Jurgita (Lithuania)
FROKJAER, Bente (Denmark)
QUISPE, Susy Olave (Spain)
SILVA, Esperança (Portugal)
SULEMAN, Fátima (S. África)

WG 2 - Home medicines delivery and pharmaceutical care provision in this context

BERNSTEN, Cecilia (Sweden)
CASSIMJEE, Mariam (S. Africa)
DAGO, Ana (Spain)
HÄMMERLEIN, Andrea (Germany)
KRUEGER, Manfred (Germany)
NAESSENS, Joke (Belgium)
SOUSA, Carla (Portugal)

Outcomes of this workshop

- 2 draft research project protocols
 - Kick-off for collaborative PCNE projects?
 - Are you keen to join us?
1. **Safety and effectiveness issues of switches to non prescription. The orlistat case.**
Contact: Suzete.Costa@anf.pt
 2. **Is home delivery service of medicines a blessing?**
Contact: cecilia.bernsten@bredband.net